Greenwich LifeSciences
February 10, 2025
Oncology
Greenwich LifeSciences (Nasdaq: GLSI) is a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating the safety and efficacy of GP2, an immunotherapy to prevent metastatic breast cancer recurrences after completion of adjuvant trastuzumab based treatment. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers. Flamingo-01 is currently expanding into Europe with up to 150 sites globally.
)
){kind=logo}
)
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}